Publications

1. Package advice venetoclax (Venclyxto®)

   The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) can be included in the insured ...

   Report | 10-11-2021

2. GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease

   The National Health Care Institute advises the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment ...

   Report | 02-11-2021

3. GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

   National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the ...

   Report | 26-10-2021

4. Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)

   Zorginstituut Nederland has completed its assessment whether cemiplimab (Libtayo®) as primary care treatment for stage IIIBC-IV ...

   Report | 26-10-2021

5. GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure

   The National Health Care Institute recommends the Minister for Medical Care to extend the reimbursement condition of ...

   Report | 21-10-2021

6. GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation

   Zorginstituut Nederland has completed its assessment whether the substance levomepromazine (Nozinan®) can be included in the ...

   Report | 29-09-2021

7. Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)

   Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...

   Report | 20-09-2021

8. GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

   The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

   Report | 17-09-2021

9. GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

   The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

   Report | 03-09-2021

10. GVS advice drospirenon-estetrol (Drovelis®)

    The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...

    Report | 31-08-2021